Milestone Pharmaceuticals (MIST) Amortization of Deferred Charges (2023 - 2026)
Milestone Pharmaceuticals (MIST) posted Amortization of Deferred Charges of $117000.0 for Q1 2026, up 1.74% on a QoQ basis from $115000.0 in Q4 2025, and up 14.71% year-over-year from $102000.0 in Q1 2025.
Milestone Pharmaceuticals (MIST) Amortization of Deferred Charges (2023 - 2026) Analysis & Trends
Milestone Pharmaceuticals' Amortization of Deferred Charges history runs 4 years deep, the most recent figure standing at $117000.0 for Q1 2026.
- Quarterly Amortization of Deferred Charges rose 14.71% year-over-year to $117000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $447000.0 (up 16.1% YoY) and the FY2025 annual result came in at $432000.0, up 16.76% from the prior year.
- Amortization of Deferred Charges was $117000.0 for Q1 2026 at Milestone Pharmaceuticals, up from $115000.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $117000.0 in Q1 2026 and bottomed at $61000.0 in Q2 2023.
- A 4-year average of $93916.7 and a median of $96000.0 in 2024 frame the typical range for Amortization of Deferred Charges.
- Annual changes were most pronounced in 2024 — Amortization of Deferred Charges soared 50.79% — and 2026, when it increased 14.71%.
- Milestone Pharmaceuticals' Amortization of Deferred Charges stood at $84000.0 in 2023, then advanced by 15.48% to $97000.0 in 2024, then climbed by 18.56% to $115000.0 in 2025, then advanced by 1.74% to $117000.0 in 2026.
- Business Quant data shows MIST's Amortization of Deferred Charges at $117000.0 in Q1 2026, $115000.0 in Q4 2025, and $109000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Milestone Pharmaceuticals | 156.34 Mn | -27.87 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 117,000.00 |
| Mar 31, 2026 | 117,000.00 |
| Dec 31, 2025 | 115,000.00 |
| Dec 31, 2025 | 115,000.00 |
| Sep 30, 2025 | 109,000.00 |
| Sep 30, 2025 | 109,000.00 |
| Jun 30, 2025 | 106,000.00 |
| Jun 30, 2025 | 106,000.00 |
| Mar 31, 2025 | 102,000.00 |
| Mar 31, 2025 | 102,000.00 |
| Dec 31, 2024 | 97,000.00 |
| Dec 31, 2024 | 97,000.00 |
| Sep 30, 2024 | 95,000.00 |
| Sep 30, 2024 | 95,000.00 |
| Jun 30, 2024 | 91,000.00 |
| Jun 30, 2024 | 91,000.00 |
| Mar 31, 2024 | 87,000.00 |
| Mar 31, 2024 | 87,000.00 |
| Dec 31, 2023 | 84,000.00 |
| Dec 31, 2023 | 84,000.00 |